FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnington,	D.C.	20549	

STATEMENT	OF CHANGES	S IN BENEFICIAL	. OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SACHS BRUCE I (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					3. I	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 11/10/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)										5. Relationship of Reporti (Check all applicable) X Director Officer (give title below) 6. Individual or Joint/Grouline)				10% Ov Other (s below)	wner specify
(Street) BOSTO	N M.	A 0.	221	0												X		filed by One filed by Mor on		•	
(City)	(St	ate) (Z	Zip)																		
		Table	I -	Non-Deriva	tive	Se	curi	ities	Acq	quir	ed, C	Disp	osed o	of, or	Benefi	cially	Own	ed			
o. ocou (o o,		2. Transaction Date (Month/Day/Ye	ar)	2A. Deem Execution if any (Month/D		Date,	Co	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				d 5) Secur Benef Owne		ities Fricially (I d Following In		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership		
									Co	Code V		Amo	ount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(IIISI	tr. 4)	(Instr. 4)
Common Stock 11/10/2020			0				P		6,825		A	\$216.47(1)(2)		18,035			D				
Common	Stock			11/10/202	0				P		4	,270	A	\$217.49(2)(3)		(3) 22,305			D		
Common Stock 11/10/2020			0				P		3,905 A \$218		\$218.7	'9(2)(4) 26		6,210		D					
		Tak	ole	II - Derivati (e.g., ρι													Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	Deemed ecution Date, ny onth/Day/Year)	Code 8)	Transaction Code (Instr.		5. Num of of Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties ed	Exp (Mo	Date Expiration Date Date Expiration Date Month/Day/Year) Date Expiration Exercisable Date		Amo Sect Und Deri Sect 3 an	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. Open market purchases reported on this line occurred at a weighted average price of \$216.47 (range \$216.01 to \$217.00).
- 2. Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
- 3. Open market purchases reported on this line occurred at a weighted average price of \$217.49 (range \$217.05 to \$218.04).
- 4. Open market purchases reported on this line occurred at a weighted average price of \$218.79 (range \$218.21 to \$219.00).

Remarks:

/s/ Sabrina Yohai, Attorney-in-11/12/2020

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.